/
Oncology
Lymphoma
549
Pipeline Programs↗
1.1K
Active Trials↗
300
Companies Involved↗
Lymphoma is a highly competitive landscape with 549 programs across 300 companies. The most active players are Regeneron, Beijing InnoCare Pharma Tech Co., Ltd., Takeda. 81 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical117
Phase 1135
Phase 2216
Phase 381
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
314 of 447 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 447 classified programs, each share of the total. Modality classified for 94% of 549 pipeline programs.
Analysis
Trial Status
3,958
clinical trials
Completed1,649 · 42%
Recruiting593 · 15%
Unknown status529 · 13%
Terminated470 · 12%
Active, not recruiting353 · 9%
Not yet recruiting184 · 5%
Other180 · 5%
Clinical Trials
Trial Activity
3958 trials
Page 1 of 264
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)